Product Compliance And Certification For Medical Device In Italy

Scope and evidence must be confirmed before any paid tests or filings.

A medical device sold in Italy does not obtain a separate “Italian CE certificate”. Its regulatory route starts with the product’s intended purpose and design under EU law, then adds applicable Italian language, registration and distribution requirements. This map concerns general medical devices, not a full procedure manual for every product.

Freeze the exact medical claim, user, patient population, model and sales channel before choosing a class or booking a notified body. “Medical device” on a commercial quotation does not establish legal qualification.

First gate: what is the product legally?

The Medical Device Regulation (EU) 2017/745 (MDR) applies to qualifying devices and accessories, with certain Annex XVI products also covered. A product’s stated medical purpose and principal mode of action matter more than its name or sales category. A device primarily analysing human specimens outside the body may instead fall under the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR).

Check whether the claimed principal action is pharmacological, immunological or metabolic; whether a medicinal substance is merely ancillary; and whether a custom-made device, investigational device or system/procedure pack route applies. Do not assume these categories use the same CE, UDI or registration procedure.

Classification triggers that change the route

For MDR devices, Annex VIII classes I, IIa, IIb and III turn on intended purpose and risk. Document each potentially applicable rule and apply the strictest relevant rule. The MDCG 2021-24 Rev.1 (April 2026) is explanatory guidance, not legislation.

What exact diagnostic, preventive, monitoring, treatment or compensatory claim appears in the IFU and advertising?
Does the device enter the body, contact injured skin, remain implanted or remain in use for a defined duration?
Is it active, delivering energy or substances, measuring, sterile or a reusable surgical instrument?
Does software drive treatment/diagnosis decisions or monitor physiological processes (Rule 11 may apply)?
Does it incorporate an ancillary medicinal substance, animal-derived material or other special-risk component?
Is the article a stand-alone device, accessory, kit, bespoke device or IVD rather than an ordinary MDR device?

Device-specific regulatory stack: decision matrix

Use this matrix to identify questions, not to assign a class without the technical file.

Product fact / trigger	Potential regulatory layer	Evidence or decision needed
Ordinary Class I candidate: non-sterile, non-measuring and not a reusable surgical instrument	MDR Annex VIII + Article 52	Confirm no higher rule; technical documentation and EU declaration remain necessary; notified body not normally involved.
Sterile, measuring or reusable surgical Class I; or IIa–III candidate	MDR Articles 51–52; notified body where required	Identify Is/Im/Ir features and the precise scope of notified-body involvement; verify body designation.
Decision-support or diagnostic software	MDR qualification + Rule 11; possible companion software rules	Record intended decisions, severity of harm, inputs, cybersecurity and clinical validation; do not classify by “app” label.
Reagents/test analysing human specimens	IVDR rather than automatically MDR	Confirm specimen, intended use and IVDR risk classification before using a generic MDR route.
Drug–device combination or substance-based product	MDR / medicinal-product borderline and consultation rules	Establish principal mode of action and whether a medicinal component is ancillary; seek specialist classification.
Electronic or wireless medical device	MDR plus potentially RoHS, radio and end-of-life legislation	Test the applicability/exclusions of each horizontal law; CE under MDR does not by itself answer them.
Individually prescribed custom-made medical device	MDR Article 2(3), Article 20(1), 21(2), Article 52(8), Annex XIII	Verify the individual written prescription and custom-made criteria. Do not assume an ordinary CE or UDI/Device route; Class III implantable custom-made devices have a specific notified-body QMS requirement.
Proposed reprocessing of a single-use device in Italy	MDR Article 17 + Italy-specific restriction	STOP: the Commission lists Italy among states that do not authorise this reprocessing. Permission in another Member State does not establish permission in Italy.
System or procedure pack containing devices	MDR Article 22 + EUDAMED rules for packs	Identify whether Article 22(1)–(3) applies or Article 22(4) treats the pack as a device; verify the responsible pack producer and device/pack registration route.

Who must assess, certify and control the device?

For an ordinary MDR device, the manufacturer establishes the quality-management and risk-control system, clinical evaluation, Annexes II–III technical documentation, conformity assessment, EU declaration of conformity, CE marking, UDI strategy and post-market surveillance. Class I is not a universal self-certification exemption: sterile, measuring and reusable surgical aspects require a notified body for the relevant aspects; higher classes ordinarily require notified-body assessment.

A manufacturer established outside the EU must designate an EU authorised representative under MDR Article 11; that representative does not have to be in Italy. Importers and distributors have separate Article 13 and 14 verification, traceability and escalation duties. A distributor translating/repackaging may trigger Article 16 requirements. An Italian reseller cannot cure missing conformity by registering a product. For EU-wide conformity process detail see the linked EU medical-device guide.

Actor registration is distinct from registering a device: manufacturers, EU authorised representatives and importers generally register in the EUDAMED Actor module. A party acting solely as a distributor need not register there as an Actor, although separate national requirements may apply. System/procedure-pack producers and custom-made-only manufacturers may have special Actor-ID rules.

Italy launch checks in 2026: EUDAMED, national records and language

EUDAMED: Since 28 May 2026, the Actor, UDI/Device, Notified Bodies & Certificates, and Market Surveillance modules are mandatory within their respective scopes. The market-surveillance module primarily concerns authorities. Device-registration transitional rules must be checked by placement date: qualifying existing devices placed before 28 May 2026 and continuing afterwards can have until 28 November 2026 for their EUDAMED device record. Do not confuse this extension with permission to market a nonconforming device.

For a device first placed on the EU market on or after 28 May 2026, check the manufacturer’s UDI/Device registration before first placement; the 28 November deadline is not a general grace period for new devices. If relying on the transitional window, retain dated evidence that the relevant device was placed on the market before 28 May and continues to be placed afterwards. Actor registration and certificate reporting have their own applicable responsibilities and transition rules.

Decide UDI/Device registration at device-identifier level (UDI-DI, or the applicable EUDAMED identifier for a legacy device), not by a broad model name: record the date of the first sales unit and any further units sharing that identifier. For identifiers first placed before 28 May 2026 and still placed afterwards, verify eligibility for the 28 November 2026 deadline. If no further units are placed after 28 May, a historical listing alone does not normally trigger registration, subject to special post-market/vigilance cases. Custom-made and investigational devices are not registered in the UDI/Device module.

Italian BD/RDM: Italy also operates a national device database/repertory used in national administration and health-service procurement. Some Ministry pages dated November 2025 discuss the pre-28 May 2026 transition; apply them together with the Ministry’s 2026 EUDAMED instructions and verify what national record, CND/EMDN mapping or procurement entry is required for the exact device and channel. Do not assume that an old blanket “register twice before any sale” statement remains correct.

Italian supply information: Legislative Decree No. 137/2022, Article 6(2), requires manufacturer-supplied written information under MDR Annex I, section 23, to be in Italian when delivered to the final user, including professionals. For implantable devices, Article 8 separately addresses implant-card information in Italian and English. Check applicable UDI label, warnings, packaging and IFU rules; an English-only IFU is not a safe default. The Commission lists Italy as not authorising reprocessing of single-use devices.

An IFU is not universally required for every device: MDR Annex I, point 23.1(d), permits omission for Class I and IIa devices that can be used safely without instructions, unless another rule in that section requires them. This exception does not waive other applicable Italian-language information.

Minimum evidence pack before an Italian launch

Build one release file that connects every marketing claim to a classification rule, evidence and Italian-facing deliverable:

Signed intended-purpose and borderline memo: images of product, claim set, audience, operating principle, alternative MDR/IVDR/medicinal routes.
Annex VIII rule-by-rule class rationale; record invasiveness, duration, activity, sterile/measuring/reusable status and software functionality.
Annex I GSPR gap assessment; risk-management file; bench, biological, electrical, software and usability tests only where relevant to actual risks.
Clinical evaluation and, where required, investigation/PMCF plan; do not use a generic literature list as a substitute for product evidence.
Annexes II–III technical file, quality-system responsibilities, applicable notified-body certificate, signed EU declaration and CE/UDI artwork.
EU authorised representative mandate where necessary; importer/distributor verification and traceability records, EUDAMED actor/device identifiers and any verified Italian national entry.
Italian label/IFU/warning control, implant card when applicable, complaints/vigilance workflow and change-control plan for claims, design, suppliers and software.

Release decision: four avoidable failure modes

STOP: “Wellness” label but diagnosis/treatment claims in advertising. Reconcile claims and qualify under MDR/IVDR before any CE route.
STOP: Class I asserted without checking sterile, measuring, reusable-surgical or Rule 11 features. Recalculate rules and notified-body need.
STOP if applicable: The CE mark and EU declaration exist, but mandatory Italian user information (including an IFU where required), EUDAMED device data or responsible-operator registration is missing. Determine which duty applies, then close that gap before the relevant placing or supply.
GO only after verification: Device identity, class, conformity, commercial operators, Italian documentation and post-market duties are aligned. Treat new indications, algorithms, materials or repackaging as reclassification/change-control triggers.

For sensor-equipped or body-worn models, compare the separate Italy wearable medical-device route; this page instead maps the cross-regime route for medical devices generally. Read the EU medical-device route for procedural detail shared across Member States.

Primary official sources

Questions manufacturers and importers ask

Does an EU CE mark automatically permit an English-only sale in Italy?

No. Applicable MDR conformity and CE marking are necessary for ordinary marketed devices, but Italian end-user information, operator duties and registration/procurement conditions must also be checked.

Must a US or UK manufacturer appoint a representative in Italy?

A non-EU manufacturer normally needs an authorised representative established in the Union under Article 11, not necessarily one established in Italy; verify its mandate and importer identity.

Can a sterile Class I device enter Italy on the declaration alone?

No. Even when the overall device is Class I, the sterile aspects require notified-body involvement under MDR Article 52. Confirm the certificate scope and Italian supply information before release.

If Italian marketing claims change for diagnostic software, can we retain the original classification?

Not automatically. Reassess device qualification, Annex VIII Rule 11, clinical purpose and plausible harm against the new Italian claim set; a CE mark on an older version does not validate expanded indications.

Was EUDAMED device registration due for all existing devices on 28 May 2026?

Not in every case. The first modules became mandatory on that date; specified already-marketed devices continuing on the market may benefit from the additional device-registration period ending 28 November 2026. Verify eligibility and other duties separately. Eligibility depends on the device identifier and continued placement, not merely a shared model name.